Taking stock of the drug industry, from the lab to the medicine chestOctober 30, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer MADS CLAUS RASMUSSEN/Ritzau Scanpix/AFP via Getty Images STAT+ | Novo Nordisk makes offer for obesity-focused Metsera, aiming to outbid Pfizer Both companies want Metsera's line of experimental weight loss drugs, as pharma firms try to gain an edge in the white-hot market. By Andrew Joseph STAT+ | How Moderna, the company that helped save the world, unraveled An in-depth analysis of Moderna's dramatic rise and fall, from mRNA triumph to existential crisis, and what its uncertain future means for biotech. By Jason Mast STAT+ | Cigna stock nosedives on news that ending PBM rebates will lower that segment's profit Cigna's plan to drop drug rebates sent its stock tumbling. The move came in response to Trump administration pressure By Tara Bannow STAT; Handout: Courtesy Eli Lilly Eli Lilly's weight loss and diabetes drug tops Keytruda as world's best-selling medicine The therapy, marketed as Zepbound and Mounjaro, took the crown from Merck's blockbuster cancer drug at a striking pace. By Elaine Chen STAT+ | Biotech might be tiny but the dealmaking is mighty Also this week: A look at Kura and Syndax as they vie for market share among AML patients, and why Intellia faces an existential crisis. By Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments